Overexpression of a dominant-negative mutant of SIRT1 in mouse heart causes cardiomyocyte apoptosis and early-onset heart failure by unknown
SCIENCE CHINA 
Life Sciences 
© The Author(s) 2014. This article is published with open access at link.springer.com life.scichina.com   link.springer.com 
                  
*Corresponding author (email: liudp@pumc.edu.cn; houzao@gmail.com) 
• RESEARCH PAPER • September 2014  Vol.57  No.9: 915–924 
 doi: 10.1007/s11427-014-4687-1 
Overexpression of a dominant-negative mutant of SIRT1 in mouse 
heart causes cardiomyocyte apoptosis and early-onset heart failure  
MU WenLi, ZHANG QingJun, TANG XiaoQiang, FU WenYan, ZHENG Wei, LU YunBiao, 
LI HongLiang, WEI YuSheng, LI Li, SHE ZhiGang, CHEN HouZao* & LIU DePei* 
State Key Laboratory of Medical Molecular Biology, Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, 
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China 
Received March 31, 2014; accepted April 30, 2014; published online August 6, 2014 
 
SIRT1, a mammalian ortholog of yeast silent information regulator 2 (Sir2), is an NAD+-dependent protein deacetylase that 
plays a critical role in the regulation of vascular function. The current study aims to investigate the functional significance of 
deacetylase activity of SIRT1 in heart. Here we show that the early postnatal hearts expressed the highest level of SIRT1 
deacetylase activity compared to adult and aged hearts. We generated transgenic mice with cardiac-specific expression of a 
dominant-negative form of the human SIRT1 (SIRT1H363Y), which represses endogenous SIRT1 activity. The transgenic 
mice displayed dilated atrial and ventricular chambers, and died early in the postnatal period. Pathological, echocardiographic 
and molecular phenotype confirmed the presence of dilated cardiomyopathy. Terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end-labeling analysis revealed a greater abundance of apoptotic nuclei in the hearts of transgenic mice. Further-
more, we show that cardiomyocyte apoptosis caused by suppression of SIRT1 activity is, at least in part, due to increased p53 
acetylation and upregulated Bax expression. These results indicate that dominant negative form of SIRT1 (SIRT1H363Y) 
overexpression in mouse hearts causes cardiomyocyte apoptosis and early-onset heart failure, suggesting a critical role of 
SIRT1 in preserving normal cardiac development during the early postnatal period. 
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SIRT1, a mammalian ortholog of yeast silent information 
regulator 2 (Sir2), is an NAD+-dependent histone and pro-
tein deacetylase and belongs to the class III HDAC family 
[1]. SIRT1 contains a highly conserved catalytic domain 
[1,2], and a point mutation in the catalytic domain effec-
tively abolishes the deacetylase activity [3,4]. The deacety-
lating substrates of SIRT1 include histones, a variety of 
important transcription factors and some transcription 
co-factors [5]. Most studies characterize that SIRT1 protects 
against aging-associated diseases including cardiovascular 
diseases, metabolic disorders, cancer and neurodegenerative 
disease [6]. SIRT1 is also crucial for improving metabolism 
and health span [79]. 
In embryo, SIRT1 expresses mainly in the heart and 
brain [10]. General knockout study shows that SIRT1 plays 
a role in heart development and morphogenesis, but there 
are a small percentage of mice survive to adulthood without 
showing heart structural abnormalities [11]. SIRT1 is highly 
expressed in the vasculature [12] and is atheroprotective in 
endothelial cells [13,14], smooth muscle cells [15] and 
macrophages [16]. SIRT1 has also been shown to protect 
hyperglycemia-induced endothelial dysfunction [17], and 
prevent vascular neointima formation [18]. In the heart, 
SIRT1 has been shown to act as an important survival factor 
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for cardiomyocytes during stress [1921]. Mild overexpres-
sion of SIRT1 in the heart protects oxidative stress-induced 
cardiac ageing and retards age-dependent cardiac dysfunc-
tion, while high levels of SIRT1 expression induces oxida-
tive stress and cardiomyopathy [22]. In addition, SIRT1 has 
the characteristics of prevention of cardiac hypertrophy 
[22,23], but it was also shown to promote cardiac hypertro-
phy and heart failure together with PPAR [24]. Further-
more, SIRT1 participates essentially in protecting hearts 
from ischemia-reperfusion injury [2527]. Several studies 
from our laboratory and others indicate that SIRT1 
deacetylase activity plays a critical role in the regulation of 
vascular function [12,2831], however, the role of deacety-
lase activity of SIRT1 in the heart is not fully investigated. 
In the present study, we demonstrate that the early post-
natal hearts express the highest level of SIRT1 deacetylase 
activity. Then we generated transgenic mice that exhibit 
cardiac-specific expression of a dominant-negative form of 
the human SIRT1 (SIRT1H363Y), which resulted in a sig-
nificant decrease in SIRT1 deacetylase activity in the hearts. 
SIRT1H363Y overexpression in mouse hearts increased 
cardiomyocyte apoptosis and caused severe dilated cardio-
myopathy, leading to deterioration of cardiac function and 
early death during the postnatal period.  
1  Materials and methods 
1.1  Assessment of SIRT1 deacetylase activity 
SIRT1 deacetylase activity was determined using the SIRT1 
Fluorimetric Kit (Biomol International, LP, Plymouth 
Meeting, PA, USA), according to the manufacturer’s in-
structions as previously described [32]. Briefly, crude nu-
clear extract samples prepared from FVB/N mice at postna-
tal age of 7 d, 2, 18 and 24 months, TG mice or WT litter-
mates on postnatal day 4 (P4) (10 μg protein/well) were 
incubated in 40 mmol L1 Tris-HCl (pH 7.4) containing 500 
µmol L1 NAD, and 100 µmol L1 Fluor de Lys-SIRT1 sub-
strate at 37°C for 1 h. Following incubation, the reaction 
was terminated by the addition of a solution containing Flu-
or de Lys Developer and 2 mmol L1 nicotinamide. Values 
were determined by reading fluorescence on a fluorimetric 
plate reader (Spectramax Gemini XPS, Molecular Devices, 
Sunnyvale, CA, USA) with an excitation wavelength of  
360 nm and emission wavelength of 460 nm.  
1.2  Generation of α-MHC-SIRT1H363Y transgenic 
mouse  
All of the animal protocols were approved by the Animal 
Care and Use Committee at the Institute of Basic Medical 
Sciences, Chinese Academy of Medical Sciences and Pe-
king Union Medical College. Full length cDNA encoding 
SIRT1H363Y was a generous gift of Prof. Fuyuki Ishikawa 
[33]. To establish transgenic mouse lines with cardi-
ac-specific expression, the DNA fragment corresponding to 
the full-length coding region of SIRT1H363Y was 
sub-cloned into the blunted SalI site of a plasmid containing 
the full-length (5.5 kb) murine α-MHC promoter [34]. 
Fragments containing the transgenic construct and the pro-
nuclear stage zygotes of FVB/N mice were used for mi-
croinjection. In all experiments, transgenic founders were 
identified and bred to produce offspring for analysis, and 
age-matched wild-type (WT) littermates were used for 
comparison with the SIRT1H363Y transgenic (TG) mice. 
Mice were anesthetized by intraperitoneal injection of 
Avertin (400 mg kg1) (Sigma-Aldrich, St. Louis, USA) and 
were euthanized by cervical dislocation prior to tissue col-
lection. 
1.3  Echocardiography 
Echocardiography was performed as previously described 
[35]. Two-dimensional short-axis images were obtained 
using a high resolution Vevo 770 Imaging System (Visu-
alsonics Inc., Toronto, Canada) equipped with a 35 MHz 
probe. Left ventricular chamber dimension and wall thick-
ness during systolic and diastolic phases were measured 
from the M-mode images. Left ventricular volume, frac-
tional shortening (FS) and ejection fraction (EF) were cal-
culated using the Vevo Analysis program. Body tempera-
ture was kept constant with a heating pad.  
1.4  Histological analysis and immunohistochemistry  
Histological analysis and immunohistochemistry were per-
formed as previously described [36]. Sections (5 μm) were 
stained with hematoxylin & eosin (H&E) and picrosirius red 
for histopathological analyses. Quantitative assessment of 
the fibrotic area of the myocardium was performed on five 
sections in five randomly selected fields per section by 
quantitative morphometry of left ventricular tissue sections. 
Paraffin-embedded sections were incubated with an-
ti-SIRT1 antibody (1:100, Santa Cruz Biotechnology Inc., 
Santa Cruz, USA) followed by biotin-streptavidin horserad-
ish peroxidase (HRP) kit (Vector Laboratory, CA, USA).  
1.5  Evaluation of apoptosis in tissue sections and car-
diomyocytes 
DNA fragmentation was detected in situ using terminal de-
oxynucleotidyl transferase-mediated dUTP nick-end label-
ing (TUNEL), as previously described [21]. Briefly, paraf-
fin-embedded sections were evaluated for apoptosis by 
means of TUNEL (DeadEnd Fluorometric TUNEL System, 
Promega, Madison, USA) according to the manufacturer’s 
protocol. Percentage of apoptosis was determined by the 
number of TUNEL positive myocytes divided by that of 
Hoechst-positive nuclei in six separate fields.  
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1.6  Primary culture of neonatal rat ventricular myo-
cytes 
Neonatal rat ventricular myocytes from 1 to 3-day-old 
Sprague-Dawley rats were prepared as previously described 
[37]. Myocytes were cultured under serum-free conditions 
for 48 h before experiments. SIRT1 inhibitor Sirtinol was 
purchased from Sigma and the Bax-inhibitory peptide V5 
and negative control peptide were purchased from Calbio-
chem (Marmstadt, Germany). 
1.7  Western blot analysis 
Western blotting was performed as previously described [21] 
with the following antibodies: anti-SIRT1, anti-Bcl-2, an-
ti-Bcl-XL, anti-Bax, anti-GAPDH (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, USA); anti-cleaved-caspase-3 
(Asp175), anti-c-FLIP, anti-caspase-8, anti-caspase-9 (Cell 
Signaling, Beverly, USA); anti-acetylated-p53 (Lys373, 
Lys382) (Upstate, New York, USA); anti-Apaf-1 (CellChip, 
Beijing, China); anti-β-Actin (Sigma, St. Louis, USA). 
Briefly, mouse hearts were homogenized in a buffer (150 
mmol L1 NaCl, 5 mmol L1 EDTA, 1% Tween-20, 50 
mmol L1 Tris, pH 7.4, protease inhibitor cocktail (Sigma, 
St. Louis, USA)), incubated on ice for 30 min, sonicated, 
then centrifuged at 25000×g for 1 h. Pellets were suspended 
in high-ionic strength buffer (1.5 mol L1 KCl rather than 50 
mmol L1 NaCl) to extract insoluble fractions. 
1.8  Polymerase chain reaction (PCR) assay 
RNA was extracted by TRIzol (Invitrogen, Carlsbad CA, 
USA). Two μg of total RNA was reverse transcribed with 
M-MuLV transcriptase (New England BioLabs, Massachu-
setts, USA) according to the manufacture’s protocol. The 
cDNAs were subjected to either conventional reverse tran-
scription PCR (SIRT1, ANP, BNP) or real-time PCR (Bax, 
Noxa, Puma and GAPDH) with SYBR Green methods. 
Primers are provided in Table S1 in Supporting Information. 
The mean expression level of each gene was normalized to 
that of GAPDH. 
1.9  Statistic analysis 
Results are expressed as mean±SEM. Differences between 
the two groups were determined by a Student’s t test. Dif-
ferences were considered significant at a value of P0.05.  
2  Results 
2.1  SIRT1 deacetylase activity is high in early postna-
tal hearts 
We first examined SIRT1 deacetylase activity in postnatal 
hearts. Crude nuclear extract samples were prepared from 
the hearts on postnatal day 7 (7D), and from the hearts of 2- 
month-old (2M), 18-month-old (18M) and 24-month-old 
(24M) mice. The postnatal day 7 hearts expressed the high-
est level of SIRT1 deacetylase activity (Figure 1), which 
was approximately 4-fold higher than the 2-month hearts 
did. The SIRT1 deacetylase activity in 18-month and 
24-month hearts was only about 10% of that on postnatal 
day 7 (Figure 1). These results suggest that SIRT1 deacety-
lase activity may play an important role in the early postna-
tal hearts. 
2.2  Characterization of SIRT1H363Y transgenic mice  
We next generated transgenic (TG) mice that expressed 
SIRT1H363Y driven by the cardiac-specific α-MHC pro-
moter (Figure 2A) to investigate the requirement for SIRT1 
deacetylase activity in the postnatal ventricular myocardium 
in vivo. This mutant SIRT1 protein has been shown to func-
tion as a potent dominant-negative inhibitor of SIRT1-  
dependent deacetylase activity [4]. Unexpectedly, most of 
the TG founder mice exhibited overt signs of heart failure, 
including shortness of breath and peripheral edema. These 
mice abated physical activity a few days before death and 
died from one week to four weeks after birth. Fortunately, 
three lines of TG founder mice (Nos. 4, 30 and 50) survived 
(Figure 2B). A robust expression of SIRT1H363Y protein 
was found in the heart (Figure 2C). No significantly pheno-
typic difference was observed among these three established 
lines of TG mice. TG4# mice expressed the highest level of 
the SIRT1H363Y protein (Figure 2B), in which cardiac 
SIRT1H363Y expression was also identified by immuno-
histochemistry (Figure 2D), and the offspring of TG4# were 
used for further experiments unless specially indicated. To 
test whether SIRT1 deacetylase activity could be inhibited 
by SIRT1H363Y overexpression, SIRT1 deacetylase activ-
ity was determined. TG mouse hearts overexpressing 
SIRT1H363Y had a 65 percent decrease in SIRT1 deacety- 
 
 
Figure 1  SIRT1 deacetylase activity in mouse hearts at different stages 
of postnatal life. SIRT1 deacetylase activity in the neonatal hearts from 
postnatal day 7 (7D), and adult hearts from 2 months (2M), 18 months 
(18M) and 24 months (24M) were examined. Extract nuclear samples were 
prepared at the indicated time points. SIRT1 deacetylase activity was de-
termined by reading fluorescence on a fluorimetric plate reader as de-
scribed under “Materials and methods”. Values are expressed as 
meanSEM (n5). ***, P0.001 vs. sample from 7D.
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Figure 2  Characterization of SIRT1H363Y TG mice. A, Diagram of the transgene construct used for the generation of SIRT1H363Y TG mice. The con-
struct contains the α-MHC promoter, the full-length human SIRT1H363Y (hSIRT1H363Y) clone and a human growth hormone poly adenylylation. B, Rep-
resentative Western blot analysis of hSIRT1H363Y protein in the heart tissue from 3 lines of TG mice and WT littermates. C, Representative Western blot 
analysis of hSIRT1H363Y protein from different organs of TG mice. D, Immunohistochemical staining for hSIRT1H363Y expression of the left ventricles 
of TG mice and WT littermates. The result shows a large increase in expression of hSIRT1H363Y in TG mouse hearts. Positive-stained cells appear brown. 
Scale bar, 50 µm. E, Deacetylase activity was evaluated for 1 h with a fluorometric assay of crude nuclear extracts from 4D old TG mouse hearts and WT 
littermates (n5). Values are expressed as mean±SEM. ***, P0.001 vs. WT. 
lase activity compared with wild-type (WT) littermates 
(Figure 2E). The fact that the dominant-negative effects of 
SIRT1H363Y protein are mostly lethal supports a crucial 
role for SIRT1 deacetylase activity in cardiomyocytes dur-
ing postnatal life. 
2.3  SIRT1H363Y transgenic mice develop dilated car-
diomyopathy and heart failure 
At birth, SIRT1H363Y TG pups were indistinguishable 
from WT littermates. Unexpectedly, they became weak and 
inactive a few days after birth and died mainly from post-
natal days 8 to 12 (Figure 3A). We analyzed the ratio of 
heart weight to body weight (HW/BW) in surviving animals 
at postnatal days 4, 6, 8 and 10, and found that the HW/BW 
ratio of TG mice was significantly greater than that of WT 
controls at postnatal days 8 and 10 (Figure 3B), indicating 
an enlargement of TG mouse hearts. TG founder mouse 50# 
died suddenly at 8 months of age. Necropsy showed en-
largement of both atria and ventricles, with a large orga-
nized thrombus in the left atrium (Figure S1A and B in 
Supporting Information), indicative of chronic heart failure. 
Using echocardiography, we discovered that left ventricular 
internal dimensions (LVID) were markedly raised in TG 
mouse hearts compared to WT littermates at P7. In addition, 
left ventricular anterior wall (LVAW) and left ventricular 
posterior wall (LVPW) of TG mice were markedly thinner 
than that in controls (Figure 3C, Table 1). These results 
suggest that the TG mice showed a phenotype of dilated 
cardiomyopathy. Functional assessment revealed significant 
augment in both diastolic and systolic ventricular chamber 
volumes, associated with abnormal cardiac function in TG 
mice, including a remarkable reduction in fractional short-
ening (FS) and ejection fraction (EF). The overall results of 
echocardiography are summarized in Table 1. We compared 
the left ventricular internal diastolic dimension (LVIDd) 
and the EF of TG mouse hearts with WT controls over five 
days of continuous observations. In TG mice, the left ven-
tricle became dilated, with an LVIDd of 2.30.19 mm, ver-
sus 1.640.04 mm in WT controls on postnatal day 6 (Fig-
ure 3D). In addition, systolic function of the TG mouse 
hearts was gradually declined, with an EF decreased to 
58%4%, versus 93.3%4.2% in WT controls on postnatal 
day 6 (Figure 3E). We further examined the mRNA level of 
atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP), two markers of molecular phenotype of heart failure. 
The results showed that ANP and BNP were up-regulated in 
TG mouse hearts (Figure 3F). These above data suggest that 
TG mice express the features of dilated cardiomyopathy 
including an early defect in contractility and rapid progres-
sion towards overt heart failure. 
To further assess alterations in the cardiac structure of 
these TG mice, we performed histological analyses. Both 
the atria and ventricles of TG mice displayed substantial 
dilatation (Figure 4A and B). Histological examination re-
vealed marked heterogeneity in cardiomyocyte size in TG 
mouse hearts, relative to WT controls (Figure 4C). However, 
no significant difference in cross-sectional area was ob-
served between WT and TG groups (Figure 4D). Picrosirius 
red staining also revealed an increased level of interstitial  
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Figure 3 (color online)  SIRT1H363Y transgenic mice developed dilated cardiomyopathy and heart failure. A, Survival curve of TG mice. The F1 genera-
tion of TG mice died mainly from postnatal day 6 to 12. Most of TG mice died at postnatal day 14 (n=24), but all WT littermates survived (n=20). B, Heart 
weight (mg) to body weight (g) ratio (HW/BW) in TG mice and WT littermates at various days. The HW/BW ratio increased in TG mice compared with WT 
littermates at postnatal days 8 and 10. Values are expressed as meanSEM (n=6). *, P0.05; **, P0.01 vs. WT. C, Echocardiograph analysis of TG mice 
and WT littermates at various days. Left ventricular internal diastolic dimension (LVIDd) (D) and ejection fraction (EF) (E) were measured by echocardiog-
raphy on conscious animals at postnatal day 4 to 8. Values are expressed as mean±SEM (n=6). **, P0.01. F, Elevated heart failure marker gene expression 
in TG mouse hearts. ANP and BNP expression of TG mouse hearts and WT littermates of P7 were analyzed by PCR with specific primers. Values are ex-
pressed as meanSEM (n=4). **, P0.01 vs. WT. 
Table 1  Echocardiograph analysis of hSIRT1H363Y TG and WT micea) 
 WT TG 
LVID; d (mm) 1.59±0.12 2.74±0.36** 
LVID; s (mm) 0.58±0.15 2.36±0.38** 
LVPW; d (mm) 0.63±0.07 0.49±0.08* 
LVPW; s (mm) 1.01±0.13 0.62±0.13** 
LVAW; d (mm) 0.69±0.08 0.46±0.07** 
LVAW; s (mm) 1.07±0.16 0.60±0.15** 
LV Vol; d (µL) 8.4±1.84 20.87±7.45** 
LV Vol; s (µL) 0.76±0.57 32.89±11.66** 
EF (%) 91.45±5.65 32.89±11.66** 
FS (%) 61.43±8.78 15.04±5.74** 
a) LVID; d/s, left ventricular diastolic/systolic internal diameter; LVPW, left ventricular posterior wall; LVAW, left ventricular anterior wall; LV Vol; 
d/s, left ventricular diastolic/systolic volume; EF, ejection fraction; FS, fractional shortening. All values are expressed as meanSD (n68). *, P0.05; **, 
P0.001 vs. WT. 
fibrosis in TG mouse hearts (Figure 4E and F). Similar 
phenomena were also observed in TG founder mouse 50# 
(Figure S1C and D in Supporting Information). By elec-
tronic microscopy analysis, typically mitochondrial deterio-
ration was found in TG mouse hearts, but not in WT con-
trols (Figure S2A and B in Supporting Information). 
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Figure 4  Histological microscopic analysis of SIRT1H363Y TG mice. A, Gross morphology of the hearts from TG mice and WT littermates. B, Micro-
scopic H&E-stained histological section of the hearts. TG mouse hearts were severely dilated in both atria and ventricles compared with those of WT con-
trols. C, H&E from the left ventricles of WT and TG mice for regular histology analysis. D, Relative cross-sectional area in (C) was quantified. ns, no sig-
nificance. n5 in each group. E, Picrosirius red staining on histological sections. Fibrosis was present in the ventricles of TG mice. F, The extent of intersti-
tial fibrosis was determined by picrosirus red staining area. Values are expressed as meanSEM. **, P0.01 vs. WT.  
2.4  Cardiomyocyte apoptosis is enhanced in TG mouse 
hearts 
Studies from our lab and others have provided evidence that 
SIRT1 can be a cell-survival factor [19,21]. This fact 
prompted us to investigate whether cardiomyocyte apopto-
sis was augmented in TG mouse hearts. We used the 
TUNEL assay to compare apoptosis between TG mouse 
hearts and those of WT littermates. The heart sections ob-
tained from TG mice exhibited a significantly larger number 
of TUNEL-positive cardiomyocytes than did controls (Fig-
ure 5A and B). Similar findings were also observed in TG 
founder mouse 50# (Figure S1E in Supporting Information). 
The level of cleaved caspase-3 was obviously increased in 
the three lines of TG mouse hearts (Figure 5C). These re-
sults indicate that cardiomyocyte apoptosis is enhanced in 
TG mouse hearts.  
2.5  TG mouse hearts show increased p53 acetylation 
and upregulated bax expression  
It has been shown that inhibiting SIRT1 can improve p53 
transcriptional activity and p53-dependent apoptosis in cul-
tured cells [3,19]. However, no significant change was ob-
served in total level of p53 protein between TG and WT 
mouse hearts. Interestingly, the level of p53 acetylation was 
significantly upregulated in TG mouse hearts (Figure 6A). 
To assess the consequence of p53 acetylation，Western blot 
analysis was performed for p53-regulated genes coding 
proteins, including Bax, Bcl-2, and Bcl-xL. The expression 
levels for Bax were approximately 2.5-fold higher in TG 
versus WT mouse hearts. Meanwhile, levels of Bcl-2, 
Bcl-XL in TG mouse hearts were similar to WT controls 
(Figure 6B). We further examined key signaling molecules 
involved in the Bax-mediated apoptosis pathway (upstream 
of caspase-3 activation) by Western blot. The level of 
Apaf-1 protein and the cleavage of caspase-9 were signifi-
cantly up-regulated in TG mouse hearts (Figure 6C), 
whereas the protein abundance of c-FLIP and caspase-8 was 
not (Figure S3 in Supporting Information). In addition, Bax 
mRNA was increased approximately 5.5-fold in TG mouse 
hearts, suggesting the transcriptional activation of this gene 
(Figure 6D). We further investigated the levels of other 
p53-regulated proapoptotic target genes, including Puma 
and Noxa. We found that the expression level for Puma was 
significantly enhanced in TG mouse hearts (Figure 6E). 
Consistent with these results in TG mice, adenoviral ex-
pression of SIRT1H363Y significantly upregulated Bax 
protein in neonatal rat ventricular myocytes, and the level of
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Figure 5  Cardiomyocyte apoptosis is enhanced in TG mouse hearts. A, TUNEL assays from TG mice and WT littermates. Representative TUNEL staining 
(top), Hoechst staining (middle), and merged image (bottom). Positive and negative controls for the TUNEL assays comprised treatment with DNase I and 
omission of TdT during the enzymatic reaction, respectively. B, Statistical summary of the assay in (A). Percentage of apoptosis was determined by the 
number of TUNEL positive myocytes divided by that of Hoechst-positive nuclei. Values are expressed as mean±SEM (n6). ** , P0.01 vs. WT. C, West-
ern blot analysis of cleaved caspase-3 expression in the three lines of TG mouse hearts and WT controls. GAPDH was used as loading control. 
p53 acetylation was also augmented. Conversely, the Bax 
protein level and p53 acetylation were reduced with adeno-
viral SIRT1 overexpression (Figure S4 in Supporting In-
formation). Overall, these data suggest that p53 acetylation 
and Bax-mediated pathway were involved in apoptosis in 
TG mouse hearts. 
3  Discussion 
It has been shown that only a small percentage of Sirt1−/− 
mice survive the first week of life [11], which supports the 
essential role of SIRT1 but makes it difficult to analyze the 
function of SIRT1 in the early stage of postnatal hearts. In 
the present study, we use a strategy to repress the deacety-
lase activity of SIRT1 in heart by cardiac-specifically over-
expressing a dominant negative form of SIRT1. This strat-
egy of repressing SIRT1 activity resulted in a series of 
phenotypes, including cardiomyocyte apoptosis associated 
with p53/Bax pathway, early-onset heart failure and prema-
ture death, which were not observed in the studies using 
conventional methods.  
We first found that the early postnatal hearts expressed 
the highest level of SIRT1 deacetylase activity (Figure 1), 
suggesting that deacetylase activity of SIRT1 is involved in 
the regulation of cardiac function in the early postnatal 
hearts. Cardiac specific SIRT1H363Y transgenic mice 
showed a significant decrease in SIRT1 deacetylase activity 
and developed dilated cardiomyopathy. Accordingly, most 
of them died from postnatal days 8 to 12 because of ear-
ly-onset heart failure (Figure 3A and F). In addition, 
high-resolution echocardiography allows direct and contin-
uous in vivo assessment of cardiac structure and function in 
the TG mice (Figure 3D and E). These results support the 
essential roles of SIRT1 deacetylase activity in the early 
stage of postnatal hearts.  
Very recently, Planavila et al. [38] showed that a small 
percentage of Sirt1−/− mice that could survive to adulthood 
developed dilated cardiomyopathy, which is somewhat sim-
ilar with the findings in TG founder mouse 50#. Thus, loss 
of SIRT1 deacetylase activity in the Sirt1−/− survivors con-
tributes to dilated cardiomyopathy in late stage of postnatal 
hearts. Here we used dominant negative form of SIRT1 
(SIRT1H363Y) overexpression to inhibit the deacetylase of 
SIRT1, whereas the study of Planavila et al. used knockout 
mice expressing a deacetylase-activity absent form of 
SIRT1 protein [38]. Compared to loss-of-function mutation 
of SIRT1 protein, dominant negative form of SIRT1 
(SIRT1H363Y) protein has potential dominant negative 
effects on cardiac functions, which may explain the more  
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Figure 6  Acetylated p53-Bax-mediated signaling pathway was involved 
in increased apoptosis in TG mouse hearts. A, Western blot analysis of p53 
expression and p53 acetylation (n=6). GAPDH was used as loading control. 
Left, representative blots; right, quantitative results. **, P0.01 vs. WT. B, 
Western blot analysis was performed to determine levels of Bax, Bcl-2 and 
Bcl-XL (n=6). GAPDH was used as loading control. Left, representative 
blots; right, quantitative results. **, P0.01 vs. WT. C, Western blot analy-
sis of important molecules in apoptosis pathways. Apaf-1 and caspase-9, 
which are important in mitochondria-mediated apoptosis (n6). GAPDH 
was used as loading control. Left, representative blots; right, quantitative 
results. *, P0.05; **, P0.01 vs. WT. D, Real-time PCR analysis of Bax 
mRNA level (n4). Bax mRNA was normalized to GAPDH mRNA. **, 
P0.01 vs. WT. E, Real-time PCR analysis of Noxa and Puma mRNA 
levels. Noxa and Puma mRNA were normalized to GAPDH mRNA (n=4). 
**, P0.01 vs. WT. 
severe phenotype of our transgenic mice, including the ear-
lier onset of cardiomyopathy and heart failure.  
Cardiomyocyte apoptosis is greatly raised in dilated car-
diomyopathy, which is characterized by the gradual devel-
opment of heart failure [39]. Both the mitochondrial and 
death receptor-initiated pathways have been shown to acti-
vate caspase-3, which is sufficient to induce cardiomyocyte 
apoptosis and dilated cardiomyopathy [40]. In the previous 
study, Planavila et al. [38] observed dilated cardiomyopathy 
and mitochondria dysfunction in SIRT1-deficient mice. 
They attributed those effects to Mef2, which is crucial both 
for cardiac differentiation and heart-specific gene expres-
sion and also for the control of mitochondrial biogenesis. 
SIRT1 is a pivotal survival factor for cardiomyocytes under 
stress [21,22]. However, it remains unclear whether SIRT1 
affects cardiomyocyte survival during the early postnatal 
period. In the present study, we systemically studied wheth-
er SIRT1 participates in cardiac function via maintaining 
cardiomyocyte survival and the underlying mechanism. Our 
results showed that the cleavage of caspase-9 was signifi-
cantly increased in TG mouse hearts (Figure 6C), whereas 
the levels of caspase-8 and its inhibitor c-FLIP were not 
increased (Figure S3 in Supporting Information). Accord-
ingly, mitochondrial deterioration was found typically in 
TG mouse hearts (Figure S2A and B in Supporting Infor-
mation). Thus, a significant increase in activation of caspa-
se-3 and cardiomyocyte apoptosis were observed in TG 
mouse hearts (Figure 5). Therefore, our data suggest that 
inhibition of SIRT1 deacetylase activity enhances mito-
chondria-associated apoptosis in cardiomyocytes and in-
duces the resultant dilated cardiomyopathy and heart failure.  
p53 acetylation correlates well with p53-mediated tran-
scriptional activation and is absolutely required for its acti-
vation as an indispensable event that enables the p53-   
mediated stress response [41]. SIRT1 activator resveratrol 
attenuates doxorubicin-induced cardiomyocyte apoptosis 
and reduces p53 acetylation [42]. Here we found that acety-
lation of endogenous p53 was significantly increased with 
SIRT1H363Y overexpression, and Bax expression was 
abundant and dramatically upregulated at both the RNA and 
protein levels in the dilated TG mouse hearts (Figure 6A, B 
and D). Bax can participate in the mitochondria-mediated 
apoptosis as an indirect target of p53 through Puma and is 
also absolutely required for Puma-mediated apoptosis [43]. 
Thus, the upregulation of Puma may augment Bax-mediated 
apoptosis as previously reported [44]. Taken together, our 
data suggest that cardiomyocyte apoptosis induced by inhi-
bition of SIRT1 deacetylase activity is, at least in part, due 
to increased p53 acetylation and upregulated Bax expres-
sion. However, other alternative pathway may exist. A re-
cent report showed that resveratrol, a known SIRT1 activa-
tor, mitigates pro-apoptotic signaling in senescent heart 
through deacetylation mechanism of SIRT1 in repressing 
Foxo1/Bim-associated pro-apoptotic signaling axis [45]. 
Additionally, a previous work showed that the effect of 
SIRT1-TG is dose-dependent [22], thus it remains further to 
investigate whether this manner exists in our system. 
In summary, we demonstrated that dominant negative 
form of SIRT1H363Y overexpression inhibits of SIRT1 
deacetylase activity in mouse heart, and causes cardiomyo-
cyte apoptosis, cardiac dysfunction, early-onset heart failure 
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and premature death. These findings suggest that SIRT1, the 
longevity gene, plays important roles not only in retarding 
age-dependent cardiac dysfunction but also in maintaining 
cardiomyocyte homeostasis and survival in the early stage 
of postnatal hearts.  
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Supporting Information 
Figure S1  Phenotypic and histological microscopic analysis of TG founder mouse 50#. A, Gross morphology of the heart from TG founder mouse 50# and 
WT littermates. Both atria and ventricles of TG founder mouse 50# displayed substantial dilation with a large organized thrombus in the left atrium. B, Tis-
sue weight to body weight ratios for TG founder mouse 50# and WT littermates. Hearts and lungs were harvested to identify mice that had signs of pulmo-
nary edema, an indication of heart failure. The heart failure phenotype of TG founder mouse 50# was determined retrospectively and was based on the crite-
rion of wet lung weight to body weight ratio. C, H&E from the left ventricles of TG founder mouse 50# and WT littermates for regular histology analysis. 
Scale bar: 50μm. D, The extent of interstitial fibrosis determined by picrosirus red staining area. Quantitative assessment of the fibrotic area of the myocar-
dium was performed in five randomly selected fields by quantitative morphometry of left ventricular tissue sections. E, Statistical summary of TUNEL as-
says from TG founder mouse 50# and WT littermates. Values are meanSEM. **, P0.01. 
Figure S2  Electron microscopic view of the ventricles of WT and TG mice. The tissue samples of the left ventricular free wall were preserved immediately 
after animal sacrifice and processed as previously described [1]. For electron microscopy, left ventricular walls from 7-day-old mice were fixed in 2.5% 
glutaraldehyde and 100 mmol L1 calcium cacodylate overnight, and subsequently postfixed with 1% OsO4; stained en bloc with 2% uranyl acetate; embed-
ded in Apon 812; sectioned; and stained with 4% uranyl acetate/Reynold’s lead citrate. The sections were examined using a JEOL TEM-1010 electron mi-
croscope (JEOL, Tokyo, Japan). By electronic microscopy analysis, mitochondrial deterioration typically was found in TG mouse hearts in B, but not in WT 
controls in A. Scale bar, 200 nm. 
Figure S3  Western blot analysis of c-FLIP and caspase-8 expression, which participate in death-receptor mediated apoptosis (n=6). GAPDH was used as 
loading control. Top, Representative blots; Bottom, quantitative results. All values are expressed as meanSEM. 
Figure S4  Western blot analysis of Bax expression and p53 acetylation in neonatal rat ventricular myocytes. To overexpress hSIRT1 and hSIRT1H363Y in 
the cardiomyocytes, an adenovirus vector expressing hSIRT1 (Ad-hSIRT1) and an adenovirus vector expressing hSIRT1H363Y (Ad-hSIRT1H363Y) were 
constructed. Packaging and amplification of adenoviral vectors were performed as previously described [2]. Adenoviral-Green Fluorescence Protein 
(Ad-GFP) was used as a control. Experiments were performed at a multiplicity of infection of 100 plaque-forming units/cell. Cardiomyocytes were infected 
with Ad-hSIRT1, control Ad-GFP or Ad-hSIRT1H363Y and Western blot analysis were performed on lysates collected 40 h after virus washout and starva-
tion. β-Actin was used as loading control. Each assay was done in triplicate. 
Table S1  Primers for conventional reverse transcription PCR or real-time PCR 
The supporting information is available online at life.scichina.com and link.springer.com. The supporting materials are 
published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely 
with the authors. 
